Health CanadaGeneral Alert
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS...
Published: April 14, 2022Recall ID: 64084Category: generalCountry: Canada
Reason for Recall / Hazard
New safety information - COVID
Product Description & Identification
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
Affected Products
Sotrovimab, 500 mg IV
Additional Source Details
| Field | Value |
|---|---|
| N I D | 64084 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/sotrovimab-injection-risk-treatment-failure-due-circulation-sars-cov-2-omicron-ba2 |
| Issue | New safety information - COVID |
| Title | Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant |
| Product | Sotrovimab, 500 mg IV |
| Archived | 0 |
| Category | Biologic or vaccine |
| Last updated | 2022-04-14 |
| Organization | Marketed health products |